Bezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile Infection
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
Previous data have shown that integrated information from single nucleotide polymorphisms
(SNPs) of the host DNA, interleukin 8 (IL-8) and the enrichment of the stool microbiome can
indicate the patients with infection by Clostridioides difficile (CDI) who are at risk for
unfavorable outcome. This integrated information is forming the BEYOND score. The aim of the
BEYOND randomized clinical trial (RCT) is to investigate if adjunctive bezlotoxumab treatment
to the current standard-of-care may decrease the likelihood of unfavorable outcome for
patients who score positive by the BEYOND score.